Exceptionally, significant new evidence may mean an update of a guideline is agreed before the next scheduled check of the need for updating (particularly when safety or safeguarding issues need to be addressed).
I think that when it comes to safety, in all walks of life, then Joe Public should not have to prove beyond doubt that something is harmful, before precautionary action is taken. Once reasonable concerns are raised, even in the form of convincing anecdotal evidence, the burden of proof should fall on the purveyors to prove an acceptable level of safety; it really should not fall on recipients to first prove harm.Can we find any examples? What level of evidence has been required in the past for them to take this action?
Can we find any examples? What level of evidence has been required in the past for them to take this action?
Well, this is where the PACE trial has been quite well designed (sarcasm), hasn't it?
They have added warnings when drugs have been labelled unsafe, I think. I'll see if I can find any examples.I think you misunderstood what I meant. I mean involving completely different conditions, not ME.
When has NICE acted on these safeguarding caveats in the past? Then, if we find examples, how do these compare? It might be that they’ve never actually responded to safeguarding issues in this way or it might be that they withdraw treatments before a review quite frequently. Quite possibly it always involves drugs and placebo controlled trials showing the drug arm causes harm.
They have added warnings when drugs have been labelled unsafe, I think. I'll see if I can find any examples.
I haven't looked but the current revelations about use of vaginal mesh implants is one to watch and see what they do. The guidelines appear to have been done last year:Can we find any examples? What level of evidence has been required in the past for them to take this action?
Not sure if this is relevant or not (drug interactions rather than contra-indications), but in case it is:I think you misunderstood what I meant. I mean involving completely different conditions, not ME.
When has NICE acted on these safeguarding caveats in the past? Then, if we find examples, how do these compare? It might be that they’ve never actually responded to safeguarding issues in this way or it might be that they withdraw treatments before a review quite frequently. Quite possibly it always involves drugs and placebo controlled trials showing the drug arm causes harm.
if you do a search on 'nice guidelines exceptional review' it comes up with loads. (I haven't looked through them).When has NICE acted on these safeguarding caveats in the past?